Vaccine, Small Molecule, Biologics CDMO
Total Trials
11
As Lead Sponsor
As Collaborator
0
Total Enrollment
2,636
NCT00778297
Immunogenicity and Tolerability Study of FluvalAB FL-K-004 Trivalent Influenza Vaccine
Phase: N/A
Role: Lead Sponsor
Start: Nov 30, 2007
Completion: May 31, 2008
NCT01010893
Tolerability and Immunogenicity of Fluval P Monovalent Influenza Vaccine
Start: Aug 31, 2009
Completion: Feb 28, 2010
NCT01407978
Tolerability and Immunogenicity Study of FLUVAL P H1N1 Flu Vaccine of Omninvest in Children and Adolescents
Completion: Mar 31, 2010
NCT01100294
Tolerability and Safety Study of FLUVAL P Monovalent Influenza Vaccine in Children
Start: Sep 30, 2009
Completion: May 31, 2010
NCT01404182
Tolerability and Immunogenicity Study of Fluval AB Influenza Vaccine in Adults and Elderly Persons
Phase: Phase 4
Start: Jul 31, 2011
Completion: Aug 31, 2011
NCT01408290
Safety and Immunogenicity Study of Fluval AB-Like Flu Vaccines With 3.5, 6, 9 or 15 μg HA in Adult and Elderly People
Start: Sep 30, 2011
Completion: Oct 31, 2011
NCT01459276
A Study to Evaluate Safety and Immunogenicity of FluvalAB-like Influenza Vaccine in Non-Elderly Adult and Elderly Subjects
Start: Oct 31, 2011
Completion: Mar 31, 2012
NCT01649713
Yearly Licence Tolerability and Immunogenicity Study of Fluval AB Seasonal Influenza Vaccine to be Used in the 2012/2013 Vaccination Season
Start: Aug 31, 2012
Completion: Sep 30, 2012
NCT01863849
Tolerability and Immunogenicity Study of Fluval AB Suspension for Injection
Start: Aug 22, 2013
Completion: Sep 17, 2013
NCT02387294
Immunogenicity and Tolerability Study of Fluval AB Novo Suspension for Injection for Children and Adolescents
Phase: Phase 3
Start: Oct 31, 2014
Completion: Dec 31, 2014
NCT03448705
Safety of 4Fluart ID Suspension for Injection in Adult Subjects
Phase: Phase 1
Start: Jan 31, 2018
Completion: Apr 3, 2018
Loading map...